| Project/Area Number |
26860949
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Psychiatric science
|
|---|
| Research Institution | Fujita Health University |
|---|
Principal Investigator |
YUKI Matsuda 藤田保健衛生大学, 医学部, 助教 (10726540)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2015: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2014: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 精神薬理学 / 精神薬理 / 統合失調症 / 抗精神病薬 |
|---|
| Outline of Final Research Achievements |
We performed multiple network meta-analysis on efficacy and safety of antipsychotics for the schizophrenia patients only biological and social homogeneous population of Japanese. As a result, we did not encounter remarkable differences in efficacy and safety compared to the previous multiple network meta-analysis intended for all races of schizophrenia (Leucht et al 2013, Lancet). In addition, to clarify the position in the outcome of antipsychotics that have been approved as a treatment for schizophrenia only in East Asia so far.
Moreover, our results suggested that clinical guidelines recommend that, "it would be performed the shared decision making of antipsychotics selection in terms of the risk of side effects".
|
